Aspirin in the Primary Prevention of Cardiovascular Disease: Current Knowledge and Future Research Needs

The totality of evidence on aspirin in the primary prevention of cardiovascular disease is incomplete, whereas it is far more robust and clear in secondary prevention. Thus, any consideration of the benefits and risks of aspirin in primary prevention should be viewed in the context of the data in secondary prevention. [1] Further, all the data on aspirin should be viewed in the context of the contributions of different types of evidence in the conclusion of a valid statistical association from analytic studies designed a priori to test a hypothesis as well as a judgment of causality based on the totality of evidence.
Source: Trends in Cardiovascular Medicine - Category: Cardiology Authors: Source Type: research